Many cancer drugs remain unproven 5 years after accelerated approval, a study finds
By CARLA K. JOHNSON AP Medical Writer The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such
Continue Reading